
1. General Information
Krabeva 400 mg Injection is an oncology medicine containing bevacizumab, a recombinant humanized monoclonal antibody and vascular endothelial growth factor (VEGF) inhibitor. The 400 mg presentation is supplied as a 16 mL single-dose vial, with a concentration of 25 mg/mL, for intravenous infusion. Krabeva is manufactured by Biocon/ Biocon Biologics.
It is a prescription medicine used under the supervision of an oncologist. The treatment regimen and dose depend on the type of cancer, overall health, and other medicines being administered.
Phoenix Exim is a medicine exporter from Nagpur, India, supplying pharmaceutical products for international markets including the USA, UK, Australia, Singapore, Canada, South Korea and UAE, subject to applicable regulatory and import requirements.
2. Product Information
| Product Detail | Information |
|---|---|
| Brand | Krabeva |
| Strength | 400 mg/16 mL |
| Active ingredient | Bevacizumab |
| Drug class | Anti-neoplastic / VEGF inhibitor |
| Dosage form | Concentrate for solution for intravenous infusion |
| Route | Intravenous (IV) infusion |
| Pack | Single-dose 16 mL vial |
| Concentration | 25 mg/mL |
| Manufacturer | Biocon / Biocon Biologics |
| Prescription | Prescription-only medicine |
Official product information confirms that each 400 mg/16 mL vial contains 400 mg of bevacizumab.
3. Uses of Krabeva 400 mg Injection
Krabeva (bevacizumab) may be prescribed, in combination with other cancer treatments or as specified by the treating oncologist, for certain cancers including:
- Metastatic colorectal cancer
- Advanced, metastatic or recurrent non-squamous non-small-cell lung cancer
- Advanced or metastatic renal cell cancer
- Persistent, recurrent or metastatic cervical cancer
- Certain epithelial ovarian, fallopian tube and primary peritoneal cancers
- Certain forms of recurrent or progressive glioblastoma, depending on the applicable product indication and treatment setting
The exact approved indications and combinations can vary by country and regulatory authority, so treatment should follow the locally approved product information.
4. Benefits of This Medicine
The principal therapeutic benefit of bevacizumab is its ability to block VEGF, a signaling protein involved in the formation of new blood vessels.
By inhibiting VEGF, bevacizumab can reduce the formation of blood vessels that tumors use to obtain oxygen and nutrients. This can help slow tumor growth and, when used with appropriate cancer therapies, may improve disease control in eligible patients.
The medicine does not work as a general cancer treatment for every cancer type; its benefit depends on the specific cancer, treatment combination and individual patient.
5. Side Effects of Krabeva 400 mg Injection
Bevacizumab can cause side effects ranging from mild to potentially serious. Possible adverse effects include:
- High blood pressure
- Nosebleeds
- Headache
- Fatigue or weakness
- Diarrhea
- Nausea
- Abdominal discomfort
- Protein in the urine
- Delayed wound healing
- Bleeding
- Blood clots
- Gastrointestinal perforation
- Infusion-related reactions
Some complications can be serious and require immediate medical attention. The official product information specifically warns about risks including gastrointestinal perforation, bleeding, hypertension, thromboembolic events and wound-healing complications.
6. Common Side Effects
Depending on the treatment regimen, commonly reported effects may include:
- High blood pressure
- Nosebleed
- Weakness or tiredness
- Nausea
- Diarrhea
- Abdominal pain
- Headache
- Reduced appetite
- Proteinuria
Patients should tell their doctor if side effects persist, become troublesome or worsen.
7. How to Use Krabeva 400 mg Injection
Krabeva should not be self-injected. It is administered as a controlled intravenous infusion by a qualified healthcare professional, generally in a hospital, clinic or oncology setting.
The dose and frequency are individualized according to the cancer being treated and the treatment regimen. Bevacizumab is commonly dosed according to body weight and may be administered at intervals such as every 2 or 3 weeks depending on the indication.
The first infusion is generally administered slowly, with subsequent infusion times adjusted according to tolerance. It should not be administered as an IV push or bolus.
8. How This Medicine Works
Krabeva contains bevacizumab, which binds to vascular endothelial growth factor (VEGF).
VEGF promotes the development of new blood vessels. Tumors can use these newly formed blood vessels to obtain oxygen and nutrients needed for growth.
By blocking VEGF, bevacizumab inhibits tumor-associated blood-vessel formation. This anti-angiogenic effect can help slow the growth and progression of certain cancers.
9. Safety Advice
- Use Krabeva only under the supervision of an oncologist or qualified healthcare professional.
- Tell your doctor about all medicines and cancer treatments you are receiving.
- Blood pressure should be monitored during treatment.
- Your healthcare team may monitor urine protein and other laboratory parameters.
- Tell your doctor if you have a history of significant bleeding, blood clots, uncontrolled hypertension, gastrointestinal problems or recent surgery.
- Bevacizumab can impair wound healing; treatment around major surgery requires careful medical planning.
- Seek urgent medical attention for severe abdominal pain, significant bleeding, chest pain, breathing difficulty, sudden neurological symptoms or a severe infusion reaction.
- Bevacizumab is contraindicated in pregnancy according to the cited product information; appropriate contraception and pregnancy counseling should be discussed with the treating physician.
- Store the product according to the manufacturer's labeled conditions. The product is a refrigerated biological medicine and should not be frozen.
- Do not use a vial if its packaging is damaged or the product has been stored outside the recommended conditions.
10. Frequently Asked Questions
Q1. What is Krabeva 400 mg Injection?
Krabeva 400 mg/16 mL is a bevacizumab-containing intravenous infusion used in the treatment of certain cancers.
Q2. What is the active ingredient in Krabeva 400 mg?
The active ingredient is bevacizumab 400 mg/16 mL.
Q3. Is Krabeva a chemotherapy medicine?
It is an anti-cancer biological medicine and is often used in combination with chemotherapy, depending on the cancer and treatment protocol.
Q4. How does Krabeva work?
It inhibits VEGF, helping prevent the formation of new blood vessels that tumors can use for growth.
Q5. How is Krabeva administered?
It is administered by intravenous infusion by a qualified healthcare professional.
Q6. Can Krabeva 400 mg be self-administered?
No. It is an IV infusion and should be administered under appropriate medical supervision.
Q7. What cancers can be treated with bevacizumab?
Depending on the approved indication and treatment regimen, bevacizumab may be used for colorectal, non-squamous NSCLC, renal, cervical and certain ovarian/fallopian-tube/primary-peritoneal cancers, among others.
Q8. Does Krabeva have serious side effects?
Yes. Although not every patient experiences them, bevacizumab can cause serious complications such as severe hypertension, bleeding, blood clots, gastrointestinal perforation and impaired wound healing.
Q9. Can Krabeva be given during pregnancy?
It is contraindicated during pregnancy according to the cited product information. Patients should discuss pregnancy and contraception with their oncologist.
Q10. What is the strength of Krabeva 400 mg?
The product contains 400 mg of bevacizumab in 16 mL, equivalent to 25 mg/mL.
Q11. Does the 400 mg vial mean every patient receives 400 mg?
Not necessarily. The prescribed dose may be calculated according to body weight and indication. The oncologist determines the appropriate dose.
Q12. Does Krabeva need refrigeration?
Yes. It should be stored according to the manufacturer's specified storage conditions and must not be frozen.
11. Substitutes for Krabeva 400 mg Injection
Potential alternatives containing bevacizumab 400 mg/16 mL include products such as Abevmy 400 mg, Bevnexxa 400 mg, Bevazza 400 mg/16 mL and Advamab 400 mg, among others. Availability and regulatory approval differ by market.
A substitute should not be selected solely on the basis of price or brand name. The treating oncologist or pharmacist should confirm the active ingredient, strength, formulation, approved indication and suitability before switching.
12. SEO Keywords
Primary Keywords
- Krabeva 400 mg Injection
- Krabeva 400 mg/16 mL
- Krabeva 400 mg supplier
- Krabeva 400 mg exporter
- Krabeva 400 mg pharmaceutical exporter
- Bevacizumab 400 mg injection
- Bevacizumab 400 mg/16 mL supplier
- Bevacizumab injection exporter India
- Krabeva injection supplier India
- Krabeva 400 mg wholesale supplier
Long-Tail B2B Keywords
- Buy Krabeva 400 mg Injection from India
- Krabeva 400 mg Injection pharmaceutical exporter from Nagpur
- Krabeva 400 mg/16 mL wholesale supplier India
- Bevacizumab 400 mg injection exporter from Nagpur India
- Krabeva 400 mg injection international pharmaceutical supplier
- Krabeva 400 mg oncology medicine exporter India
- Bevacizumab 400 mg oncology injection supplier India
- Krabeva 400 mg injection B2B pharmaceutical supplier
- Krabeva 400 mg injection bulk supplier India
- Krabeva 400 mg injection for international pharmaceutical buyers
- Krabeva 400 mg injection supplier for USA
- Krabeva 400 mg injection supplier for UK
- Krabeva 400 mg injection supplier for Australia
- Krabeva 400 mg injection supplier for Singapore
- Krabeva 400 mg injection supplier for Canada
- Krabeva 400 mg injection supplier for South Korea
- Krabeva 400 mg injection supplier for UAE
- Bevacizumab 400 mg injection exporter to USA
- Bevacizumab 400 mg injection exporter to UK
- Bevacizumab 400 mg injection exporter to Australia
- Bevacizumab 400 mg injection exporter to Canada
- Bevacizumab 400 mg injection exporter to UAE
- Krabeva 400 mg oncology medicine supplier Nagpur India
- Biocon Krabeva 400 mg injection supplier India
- Krabeva 400 mg bevacizumab wholesale pharmaceutical exporter
- Indian pharmaceutical exporter for Krabeva 400 mg injection
- trusted pharmaceutical exporter for oncology medicines from India
- oncology medicine supplier from Nagpur India
- anti-cancer injection exporter from India
- pharmaceutical wholesale supplier for international markets
Keywords







